SIPAD

Currently, we administer immunoglobulin substitution therapy to children and adults with recurrent respiratory infections because of an antibody deficiency. The main objective of this therapy is to prevent cumulative lung damage caused by recurrent respiratory infections experienced by these patients.

However, systemic (blood) immunoglobulin suppletion may not reach the respiratory tract in sufficient concentrations. Indeed, lung damage despite immunoglobulin substitution therapy is still observed in these patients.

Local antibody concentrations, that can be measured in respiratory secretions such as saliva, may play a more significant role in preventing lung damage. Therefore, we aim to investigate the role of local IgG in saliva in preventing lung damage through immunoglobulin substitution therapy.